CBP + 5-fluorouracil

CBP + 5-fluorouracil is a combination therapy consisting of CBP (CREB-binding protein) modulation and the antimetabolite chemotherapeutic agent 5-fluorouracil. While "CBP" most commonly refers to a cellular protein (CREB-binding protein), in the context of drug combinations, it may also refer to an investigational compound targeting or modulating CBP activity. However, there is no evidence from current clinical trials or literature that a marketed pharmaceutical product named "CBP" exists as a standalone drug; rather, research focuses on the role of CBP in cancer biology and its interaction with drugs like 5-fluorouracil[1]. 5-Fluorouracil (5-FU) is a well-established small molecule chemotherapeutic that inhibits thymidylate synthase, thereby disrupting DNA synthesis and repair. It also induces global histone deacetylation by promoting degradation of p300/CBP via chaperone-mediated autophagy[1]. This effect can sensitize cancer cells to chemotherapy by altering chromatin structure and gene expression. The combination aims to exploit this synergy for enhanced anti-tumor efficacy, particularly in colorectal cancer and other solid tumors where resistance to 5-FU may be linked to p300/CBP expression levels[1].